Table 3.

Cutaneous adverse events induced by targeted therapies: synthesis table.

	EGFRi	c-kit inhibitors BCR–ABLi	Angiogenesis agents	FGFRi	BRAFi	MEKi	mTORi PI3Ki	HHi	JAKi	PARPi
Papulopustular eruption	X					X
Exanthema (nonspecific rash)		X			X	X
Keratinocytic proliferation Eruption Benign and malignant neoplasms		X	X		X X		X		X
Hand–foot skin reaction			X	X	X
Hair changes (alopecia, trichomegaly, hirsutism, kinking)	X		X	X
Nail changes Paronychia and pyogenic granuloma Onycholysis	X			X		X
Xerosis/fissures	X			X		X
Oral Mucositis Stomatitis Dysgeusia Xerostomia	X			X			X	X
Hypopigmentation		X	X
Photosensitivity reaction	X				X					X
Panniculitis					X
Melanocytic lesion changes					X

BCR–ABLi = breakpoint cluster region gene–Abelson proto-oncogene inhibitors; EGFRi = epidermal growth factor receptor inhibitors; FGFRi = fibroblast growth factor receptor inhibitors; HHi = hedgehog inhibitors; JAKi = Janus kinase inhibitos; MEKi = mitogen-activated extracellular kinase inhibitors; mTORi = mammalian target of rapamycin inhibitors; PARPi = poly-ADP ribose polymerase inhibitors; PI3Ki = phosphatidylinositol-3-kinase inhibitors